Physiology Department at Poznan University of Medical Sciencesš
Dr. Joanna Bartkowiak-Wieczorek is a distinguished pharmacogeneticist and Assistant Professor at the Medical University of Karol Marcinkowski in PoznaÅ. She holds a Masterās in Biological Sciences from Adam Mickiewicz University, where she first explored molecular biology, and earned her Ph.D. at the Medical University of PoznaÅ, focusing on genetic markers related to osteoporosis. With expertise in pharmacogenetics, biochemistry, and molecular biology, Dr. Bartkowiak-Wieczorekās research examines gene-drug interactions and plant-based compounds, particularly cannabinoids in oncology. A committed educator, she teaches pharmacology and quality management, instilling rigorous standards in future healthcare professionals. Her work in personalized medicine and dedication to research quality has garnered significant recognition and establishes her as a leading figure in pharmacogenetics.
Professional ProfileĀ
Education š:
Dr. Joanna Bartkowiak-Wieczorek holds a Master of Science in Biological Sciences from Adam Mickiewicz University, PoznaÅ, where she specialized in molecular biology, conducting research on modified DNA bases. She earned her Ph.D. from the Medical University of PoznaÅ and Adam Mickiewicz University, focusing on genetic polymorphisms related to osteoporosis risk. Her doctoral work on estrogen and calcitonin receptors laid the foundation for her expertise in pharmacogenetics.
Work Experience š¼:
Dr. Bartkowiak-Wieczorek is currently an Assistant Professor and research staff member at the Medical University of Karol Marcinkowski in PoznaÅ, where she has been teaching and conducting research since 2018. Previously, she worked at the Medical University of PoznaÅ, focusing on pharmacogenetics research and quality management in drug development. She also contributed to the Institute of Natural Fibres and Medicinal Plants, PoznaÅ, implementing ISO and GMP standards, which supports her commitment to rigorous quality in research and clinical practices.
Skills š
Dr. Bartkowiak-Wieczorek is skilled in pharmacogenetic analysis, biochemistry, and molecular biology techniques, including DNA isolation, PCR, and ELISA. She has a strong foundation in quality management, having implemented GMP, ISO 9001, and ISO 17025 standards in clinical and preclinical studies. Her expertise also extends to pharmacogenetic testing, pharmacotherapy, and plant-based compound analysis, notably with cannabinoids.
Awards and Honors š
Dr. Bartkowiak-Wieczorek is skilled in pharmacogenetic analysis, biochemistry, and molecular biology techniques, including DNA isolation, PCR, and ELISA. She has a strong foundation in quality management, having implemented GMP, ISO 9001, and ISO 17025 standards in clinical and preclinical studies. Her expertise also extends to pharmacogenetic testing, pharmacotherapy, and plant-based compound analysis, notably with cannabinoids.
š¤ Memberships:
Dr. Bartkowiak-Wieczorek is actively involved in several scientific communities, contributing her knowledge in biochemistry, pharmacology, and personalized medicine. Her collaborative work with institutions such as the National Science Centre and participation in interdisciplinary research projects demonstrate her dedication to advancing pharmacogenetics and biopharmacy.
Teaching Experience š©āš«:
She has extensive teaching experience, instructing students in various programs, including Medicine, Pharmacy, and Dentistry, at the Medical University of Karol Marcinkowski. Her courses cover human physiology, pharmacology, pharmacogenetics, and quality management, reflecting her comprehensive approach to teaching future medical professionals.
Research Focus š¬:
Dr. Bartkowiak-Wieczorekās research centers on pharmacogenetics, particularly the interaction of genetics with drug efficacy and safety. She explores plant-based compounds, with a specific focus on cannabinoids and their applications in oncology and chronic disease management. Her research projects include studies on gene expression, drug interactions, and the pharmacokinetics of pediatric treatments, which contribute to the field of personalized medicine.
š PublilcationĀ
- Cannabis sativa L. Extract Alleviates Neuropathic Pain and Modulates CB1 and CB2 Receptor Expression in Rat
2024, Biomolecules, 14(9), 1065
- Methylsulfinyl Hexyl Isothiocyanate (6-MSITC) from Wasabi Is a Promising Candidate for the Treatment of Cancer, Alzheimerās Disease, and Obesity
2024, Nutrients, 16(15), 2509
- The Dual Faces of Oestrogen: The Impact of Exogenous Oestrogen on the Physiological and Pathophysiological Functions of Tissues and Organs
2024, International Journal of Molecular Sciences, 25(15), 8167
- Natural Products and Health
2024, Nutrients, 16(3), 415
- THC-Reduced Cannabis sativa L.āHow Does the Solvent Determine the Bioavailability of Cannabinoids Given Orally?
2023, Nutrients, 15(12), 2646
- Krytyczne spojrzenie na nowe możliwoÅci zastosowania terapeutycznego statyn ā podsumowanie aktualnego stanu wiedzy
2023, Farmacja Polska, 79(5), 297-315
- The Dark Side of Iron: The Relationship between Iron, Inflammation and Gut Microbiota in Selected Diseases Associated with Iron Deficiency AnaemiaāA Narrative Review
2022, Nutrients, 14(17), 3478
- High-fat, Western-style diet, systemic inflammation, and gut microbiota: A narrative review
2021, Cells, 10(11), 3164
- The Effect of Genetic Variations for Interleukin-10 (IL-10) on the Efficacy of Immunosuppressive Therapy in Patients after Kidney Transplantation
2020, International Immunopharmacology, 89, 107059
- The Effect of Different Water Extracts from Platycodon grandiflorum on Selected Factors Associated with Pathogenesis of Chronic Bronchitis in Rats
2020, Molecules (Basel, Switzerland), 25(21)B